国科恒泰（北京）医疗科技股份有限公司 独立董事 2024 年度述职报告 （张金鑫） 各位股东及股东代表： 本人作为国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）独 立董事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"）等有 关法律法规以及《公司章程》《独立董事工作制度》等有关规定，切实履行忠实 诚信和勤勉尽责的义务，充分发挥独立董事作用，维护公司整体利益和全体股东 的合法权益。现就 2024 年度工作情况汇报如下： 一、独立董事基本情况 （一）个人基本情况 张金鑫，男，1971 年 10 月出生，中国国籍，无境外永久居留权，博士学历。 1994 年 7 月至 1997 年 9 月，就职于煤炭科学研究总院职业医学研究所，任实习 研究员。2000 年 3 月至 2001 年 9 月，就职于联想集团有限公司，任发展战略部 分析员。2005 年 7 月至 2017 年 9 月，就职于北京交通大学，历任经济管理学院 会计学讲师、副教授，会计系副主任。2017 年 9 月至今，就职于诚通基金管理 有限公司，任研究规划部总经理。截至本报告披露日，任山西锦波生物医药股份 有限公司独立董事、华泰证券股份有 ...

国科恒泰（北京）医疗科技股份有限公司 独立董事 2024 年度述职报告 （陈鑫） 各位股东及股东代表： 本人作为国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）独 立董事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"）等有 关法律法规以及《公司章程》《独立董事工作制度》等有关规定，切实履行忠实 诚信和勤勉尽责的义务，充分发挥独立董事作用，维护公司整体利益和全体股东 的合法权益。现就 2024 年度工作情况汇报如下： 一、独立董事基本情况 （一）个人基本情况 陈鑫，女，1976 年 1 月出生，中国国籍，无境外永久居留权，博士学历。 2004 年 10 月至 2007 年 10 月，就职于中国社会科学院法学研究所，任博士后研 究人员、副研究员。2007 年 9 月至 2017 年 9 月，就职于中国青年政治学院法律 系，任民商法室主任。2017 年 9 月至今，就职于中国社会科学院大学，任法学 院教师。截至本报告披露日，任北京首钢朗泽科技股份有限公司独立董事。现任 公司独立董事。 （二）独立性情况说明 作为公司的独立董事，本人符合《上市公司独立董事管理办法》对独立性的 要求，不存在影响独立性 ...

国科恒泰（北京）医疗科技股份有限公司董事会 根据中国证券监督管理委员会《上市公司独立董事管理办法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等要求，国科恒泰（北京）医疗科技股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事张金鑫、姜涟、陈鑫的独立性情 况进行评估并出具如下专项意见： 经核查独立董事张金鑫、姜涟、陈鑫及前述独立董事的直系亲属和主要社会 关系人员的任职经历以及独立董事签署的相关自查文件，上述人员均未在本公司 担任除独立董事外的其他职务，并与本公司及本公司主要股东不存在直接或者间 接利害关系或者其他可能影响其进行独立客观判断的关系，符合《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》中对独立董事独立性的相关要求。 国科恒泰（北京）医疗科技股份有限公司 董事会对独董独立性评估的专项意见 2025 年 4 月 24 日 ...

Financial Performance - The basic earnings per share decreased by 22.22% from 0.36 yuan in 2023 to 0.28 yuan in 2024 [1] - Operating revenue fell by 1.83% from 74.83 billion yuan in 2023 to 73.46 billion yuan in 2024 [1] - Net profit decreased by 14.94% from 1.54 billion yuan in 2023 to 1.31 billion yuan in 2024 [1] - Return on equity dropped by 35.13% from 8.17% in 2023 to 5.30% in 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 18,437.1 million shares, accounting for 56.94% of the circulating shares, with a decrease of 1,507.37 million shares compared to the previous period [1] - The largest shareholder, Holguos Hongsheng Ruitai Equity Investment Management Partnership, holds 6,364.74 million shares, representing 19.66% of the total share capital [2] - The second-largest shareholder, Taikang Life Insurance Co., Ltd., holds 3,641.69 million shares, accounting for 11.25% of the total share capital [2] Dividend Distribution - The company announced a dividend distribution plan of 0.84 yuan per share (including tax) [3]

Financial Performance - The company's revenue for 2024 is approximately ¥7.35 billion, a decrease of 1.82% compared to ¥7.48 billion in 2023[20]. - Net profit attributable to shareholders for 2024 is approximately ¥130.66 million, down 15.09% from ¥153.88 million in 2023[20]. - The net profit after deducting non-recurring gains and losses is approximately ¥116.92 million, a decline of 21.56% from ¥149.05 million in 2023[20]. - Cash flow from operating activities for 2024 is approximately ¥649.14 million, a decrease of 9.49% compared to ¥717.20 million in 2023[20]. - Basic and diluted earnings per share for 2024 are both ¥0.28, down 22.22% from ¥0.36 in 2023[20]. - Total assets at the end of 2024 are approximately ¥6.64 billion, a decrease of 5.68% from ¥7.04 billion at the end of 2023[20]. - Net assets attributable to shareholders at the end of 2024 are approximately ¥2.48 billion, an increase of 1.05% from ¥2.45 billion at the end of 2023[20]. - The weighted average return on equity for 2024 is 5.30%, down from 8.17% in 2023, reflecting a decrease of 2.87%[20]. - The company's operating revenue for the reporting period was approximately CNY 1.71 billion, a decrease of 11.8% compared to the previous year[23]. - Net profit attributable to shareholders was approximately CNY 27.61 million, down 21.9% year-over-year[23]. - The net cash flow from operating activities was CNY 238.28 million, a significant increase compared to the previous year's negative cash flow of CNY -57.92 million[23]. Market Outlook - The medical device industry in China is projected to reach a market size of CNY 111.03 billion in 2024, driven by aging population and technological innovation[29]. - By the end of 2024, the population aged 60 and above in China is expected to reach 310 million, accounting for 22% of the total population[29]. - The global high-value medical consumables market is estimated to approach USD 180 billion in 2024, despite facing challenges from rising raw material prices and geopolitical tensions[33]. - In 2024, the population aged 65 and above in China is expected to exceed 220 million, accounting for 15.6% of the total population, indicating a significant demand for medical devices due to aging-related health issues[64]. - The national urbanization rate is projected to reach 67% by the end of 2024, indicating a growing market for medical devices in urban areas[64]. Strategic Initiatives - The company aims to become a leading digital supply chain service provider in the medical device industry in China, focusing on distribution and direct sales of medical devices[36]. - The company has developed a comprehensive digital supply chain service platform, integrating logistics, capital flow, and information flow for traceability and efficiency[46]. - The company is actively participating in hospital SPD projects, optimizing supply chain management and reducing procurement costs for medical institutions[43]. - The company aims to enhance its profitability by increasing investments in information systems and developing a digital supply chain service[49]. - The company is focused on high-quality development and increasing profitability through strategic planning and operational improvements for 2025[130]. - The company is committed to optimizing its national business layout and enhancing service capabilities to ensure stable product supply amidst potential policy changes in the medical device industry[135]. Research and Development - The number of R&D personnel increased to 61 in 2024, up 15.09% from 53 in 2023[98]. - R&D investment amounted to ¥25,847,472.64 in 2024, significantly higher than ¥12,903,071.91 in 2023[98]. - R&D expenditure accounted for 0.35% of total revenue, a significant increase from 0.17% in the previous year[99]. - The company is investing heavily in R&D, with a budget allocation of $50 million for the development of new technologies in the upcoming year[182]. Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, continuously improving its corporate governance level[149]. - The board of directors consists of 9 members, including 3 independent directors, and has set up four specialized committees to enhance operational compliance[152]. - The company maintains strict independence from its controlling shareholders in terms of assets, personnel, finance, institutions, and business operations, ensuring no infringement on shareholder interests[158][159][160][161][162]. - The company has a dedicated financial department with an independent accounting system and financial management policies, ensuring autonomous financial decision-making[160]. - The company emphasizes investor relations management, ensuring transparent information disclosure and equal access for all shareholders[156]. Investor Relations - The company held investor communication activities on January 24, February 23, and February 29, 2024, to discuss business operations and industry trends[144]. - The company plans to disclose its 2023 annual and 2024 Q1 performance on May 16, 2024, with further details to be provided on May 30, 2024[145]. - The company is actively engaging with various investment institutions, including Huatai Securities and CITIC Securities, to discuss future strategies and market expansion[145]. - The company is dedicated to sharing insights and trends in the industry to better inform its stakeholders[144]. Operational Efficiency - The company has implemented a fully online management system for business processes, achieving 100% digitalization of operations, which enhances efficiency and reduces operational risks[68]. - The company is focusing on enhancing the automation of order processing and financial management through system integration with existing business operations[96]. - The company has invested hundreds of millions in digital transformation, achieving full online management of business processes, which significantly improves operational efficiency[132]. - The company has established 119 logistics distribution centers nationwide, enabling a two-hour delivery service to over 80% of tertiary hospitals, enhancing operational efficiency[67]. Risk Management - The company emphasizes that forward-looking statements do not constitute a commitment to investors and are subject to market conditions[4]. - The company has outlined potential risk factors and countermeasures in the management discussion and analysis section[4]. - The company faces risks related to industry policy changes, market consolidation, and competition, which could impact its operational performance if not managed effectively[134][136]. Shareholder Engagement - The company plans to hold a shareholders' meeting on September 23, 2024, to review the handling of surplus fundraising funds[116]. - The company has conducted regular shareholder meetings, ensuring equal rights for all shareholders, particularly minority shareholders[150]. - The company has approved the proposal to use part of the raised funds for permanent working capital supplementation[164].

Financial Performance - The company's revenue for Q1 2025 was ¥1,738,389,865.52, representing a 1.40% increase compared to ¥1,714,442,628.85 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥8,952,497.24, a decrease of 132.43% from a profit of ¥27,605,497.74 in Q1 2024[5]. - The basic and diluted earnings per share were both -¥0.02, down 133.33% from ¥0.06 in Q1 2024[5]. - The net profit for the current period was a loss of ¥6,650,759.09, compared to a profit of ¥22,486,267.38 in the previous period, indicating a significant decline[17]. - The total equity attributable to shareholders decreased to ¥2,467,973,507.42 from ¥2,476,954,312.99, a decline of about 0.4%[15]. Cash Flow - The net cash flow from operating activities increased by 66.97% to ¥397,850,648.04, up from ¥238,278,290.73 in the previous year[5]. - Cash inflows from operating activities totaled ¥2,729,858,025.46, compared to ¥2,542,690,585.01 in the previous period, showing an increase of approximately 7.4%[20]. - The net cash flow from operating activities was $397,850,648.04, an increase of 67.0% compared to $238,278,290.73 in the previous period[21]. - Cash outflows from operating activities totaled $2,332,007,377.42, slightly up from $2,304,412,294.28[21]. - The ending cash and cash equivalents balance was $776,435,601.72, slightly down from $777,645,427.97[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,717,218,015.57, a 1.22% increase from ¥6,636,569,329.88 at the end of the previous year[5]. - The total liabilities amounted to ¥4,168,470,329.19, up from ¥4,073,989,164.42, marking an increase of approximately 2.3%[15]. - Total current liabilities amounted to CNY 3,983,361,524.45, up from CNY 3,889,174,013.87, reflecting an increase of approximately 2.41%[14]. - The total liabilities of the company were CNY 3,983,361,524.45, which is a significant portion of the total assets, indicating a leverage ratio that needs to be monitored[14]. Shareholder Information - The company reported a total of 18,479 common shareholders at the end of the reporting period[10]. - The largest shareholder, Dongfang Keyi Holdings, holds 30.13% of the shares, totaling 141,776,229 shares[10]. Operating Costs and Expenses - The company experienced significant increases in costs and credit impairment provisions, impacting profitability negatively[8]. - Total operating costs increased to ¥1,734,948,645.53 from ¥1,682,127,917.55, representing a rise of about 3.1%[16]. - Research and development expenses decreased to ¥1,288,251.67 from ¥2,461,677.45, a reduction of about 47.7%[17]. - Cash paid to employees increased to $64,803,335.04 from $61,868,994.72, reflecting a growth of 3.1%[21]. - Cash paid for taxes decreased significantly to $44,015,135.77 from $67,343,262.06, a reduction of 34.6%[21]. - Cash paid for other operating activities surged to $582,010,204.79 from $216,527,081.68, an increase of 169.5%[21]. Non-Recurring Items - Non-recurring gains and losses totaled ¥1,927,007.85 for the reporting period[7]. - The company recorded a credit impairment loss of -¥8,139,211.67, contrasting with a gain of ¥1,610,263.03 in the previous period[17].

2025年4月16日，谊安医疗与国科恒泰供应链管理有限公司在北京举行医疗器械流通创新合作研讨会， 双方围绕"平台型供应链 + 精准独家代理"模式展开深度解读。 模式创新落地：三大赋能构建渠道生态新范式 数据显示，2025 年一季度双方合作已取得突破性进展： 战略合作：与国科恒泰、九州通供应链达成年度 2.8 亿元合作框架，落地北京、西南两大区域中心仓； 双方联合推出的"平台 + 精准独代"模式，通过供应链平台与渠道网络的深度耦合，实现生产企业、平台 商、代理商三方价值重构： 轻资产运营：代理商告别千万级预付款模式，由国科恒泰 126 个城市子公司承担仓储配送，备货资金压 力直降 70%，聚焦核心医院市场开拓； 全资质共享：依托国科恒泰国资背景与全国招投标资质（覆盖 31 个省份，税务评级 A 级占比 60%）， 代理商可无缝参与各地集采项目，突破区域准入壁垒； 金融活水注入：针对大型医疗设备采购项目，平台提供低息供应链金融产品。 国科恒泰总经理曹劲慈特别强调模式的可复制性："我们在医用耗材领域验证的'短期寄售 + 动态库 存'机制，已平移至设备流通场景，目标是让代理商从'资金掮客'转型为'临床服务专家'。" ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-014 国科恒泰（北京）医疗科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）会议的召开情况 1、会议的召开时间： 现场会议时间：2025 年 3 月 24 日（星期一）下午 14:30 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 3 月 24 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00；通过深圳证券交易所互 联网系统投票的具体时间为：2025 年 3 月 24 日上午 9:15 至下午 15:00 的任意时 间。 2、会议召开地点：北京市北京经济技术开发区经海四路 25 号 6 号楼公司 410 会议室。 1、股东出席的总体情况 通过现场和网络投票的股东及股东代表 130 人，代表股份 125,414,363 股，占 公司有表决权股份总 ...

北京市中伦律师事务所 关于国科恒泰（北京）医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年三月 務 所 法律意见书 目 录 | | 本次股东大会的召集、召开程序… | | --- | --- | | ן 1 | 出席本次股东大会人员和会议召集人资格 … | | 11 | 本次股东大会的表决程序和表决结果 | | 四、 | 结论意见… | 2 北京市中伦律师事务所 关于国科恒泰（北京）医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：国科恒泰（北京）医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）受国科恒泰（北京）医疗科技 股份有限公司（以下简称"公司"）委托，指派律师见证公司 2025 年第一次临时 股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东大会规则》等相关法律、法规、规范 性文件及《国科恒泰（北京）医疗科技股份有限公司章程》（以下简称"《公司章 程》"）的规定，对本次股东大会进行见证并出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 ...

编号：2025-004 投资者关系活 动类别 ☑特定对象调研 □分析师会议 □媒体采访 □新闻发布会 □现场参观 □业绩说明会 □路演活动 □其他(请文字说明其他活动内容) 参与单位名称 及人员姓名 国泽基金 刘继勇 深圳国金资产 王涛 国中长城资产管理 李泽阳 偕沣资产 王荣风 个人投资者 刘立伟 时间 2025年3月18日（星期二）10:30 地点 公司会议室 上市公司接待 人员姓名 副总经理、董事会秘书：王小蓓 证券事务代表：林芬芬 投资者关系经理：丁晓庄 投资者关系活 动主要内容介 绍 公司接待人员就与会人员提出的问题逐一解答。 1、公司的商业模式是怎样的？在医疗器械产业链当中承担什么角 色？ 答：公司基于"短链+数字化赋能"的设计理念，创新性地打造了"一 站式分销平台+院端服务平台"的商业模式；通过集中整合资金、仓 储、物流、信息等关键要素，为本行业提供从生产厂家到手术室的 整体数字化供应链，涵盖出厂、流通、入院、手术配台、跟台等全 链条综合专业化服务，助力解决了过去传统经销商服务中"多、小、 散、乱"的问题，确保带量采购后医疗器械临床供应的稳定性，成 为国家医改政策落地的抓手和条件保障。 2、公司 ...